I had been falling a lot. It was almost as if my small feet were suddenly too big. Then my symptoms took a darker turn. “I can’t see!” I gasped one frigid January morning in 1997. Beside me, my ...

Tolebrutinib treatment associated with 31% risk reduction in 6-month confirmed disability progression vs placebo. HealthDay News — Tolebrutinib, a brain-penetrant and bioactive Bruton tyrosine ...

may fill a significant unmet need by delaying disability progression in patients with non-relapsing secondary progressive multiple sclerosis. “Tolebrutinib represents a new class of therapy for the ...

Lack of pain Ischemic optic neuropathy, NMO-associated optic neuritis ... urgent evaluation for progressive multifocal leukoencephalopathy. Uveitis affects 1–2% of MS patients and usually ...

About 85% of MS cases begin as the relapsing-remitting form, and over 10-20 years, a large proportion of patients transition to secondary progressive MS, where relapses subside and are gradually ...

slows disability progression in adults with nonrelapsing secondary progressive multiple sclerosis (MS). HealthDay News — Tolebrutinib, a brain-penetrant and bioactive Bruton tyrosine kinase inhibitor ...

The New England Journal of Medicine (NEJM) published positive results from the HERCULES phase 3 study demonstrating that tolebrutinib delayed disability progression in people with non-relapsing ...

Glaucoma is actually a group of eye diseases that damage the optic nerve in the back of the eye and cause vision loss and blindness. The most common type in the United States is open-angle glaucoma.

Robert J. Fox, M.D., from the Mellen Center for Multiple Sclerosis at the Cleveland Clinic, and colleagues conducted a phase 3, double-blind, event-driven trial involving 1,131 adults (age range ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib ...

Get Instant Summarized Text (Gist) Tolebrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, shows potential in reducing disability progression in non-relapsing progressive multiple sclerosis (MS ...